Lidds AB (LIDDS) - Total Assets
Based on the latest financial reports, Lidds AB (LIDDS) holds total assets worth Skr1.98 Million SEK (≈ $213.40K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See LIDDS net asset value for net asset value and shareholders' equity analysis.
Lidds AB - Total Assets Trend (2010–2024)
This chart illustrates how Lidds AB's total assets have evolved over time, based on quarterly financial data.
Lidds AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Lidds AB's total assets of Skr1.98 Million consist of 80.1% current assets and 19.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr5.51 Million | 67.5% |
| Accounts Receivable | Skr221.00K | 2.7% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr1.39 Million | 17.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Lidds AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lidds AB stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lidds AB's current assets represent 80.1% of total assets in 2024, an increase from 18.4% in 2010.
- Cash Position: Cash and equivalents constituted 67.5% of total assets in 2024, up from 12.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 1.0% in 2010.
- Asset Diversification: The largest asset category is cash and equivalents at 67.5% of total assets.
Lidds AB Competitors by Total Assets
Key competitors of Lidds AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Lidds AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.04 | 5.61 | 3.39 |
| Quick Ratio | 4.04 | 5.61 | 3.20 |
| Cash Ratio | 3.53 | 4.76 | 0.00 |
| Working Capital | Skr1.49 Million | Skr6.35 Million | Skr27.18 Million |
Lidds AB - Advanced Valuation Insights
This section examines the relationship between Lidds AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -53.8% |
| Total Assets | Skr8.16 Million |
| Market Capitalization | $361.27K USD |
Valuation Analysis
Below Book Valuation: The market values Lidds AB's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lidds AB's assets decreased by 53.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lidds AB (2010–2024)
The table below shows the annual total assets of Lidds AB from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr8.16 Million ≈ $877.93K |
-53.79% |
| 2023-12-31 | Skr17.66 Million ≈ $1.90 Million |
-31.89% |
| 2022-12-31 | Skr25.92 Million ≈ $2.79 Million |
-53.36% |
| 2021-12-31 | Skr55.58 Million ≈ $5.98 Million |
+2.53% |
| 2020-12-31 | Skr54.20 Million ≈ $5.83 Million |
-65.71% |
| 2019-12-31 | Skr158.09 Million ≈ $17.01 Million |
-3.24% |
| 2018-12-31 | Skr163.38 Million ≈ $17.58 Million |
+24.90% |
| 2017-12-31 | Skr130.81 Million ≈ $14.08 Million |
+8.10% |
| 2016-12-31 | Skr121.01 Million ≈ $13.02 Million |
+18.24% |
| 2015-12-31 | Skr102.35 Million ≈ $11.01 Million |
+3.70% |
| 2014-12-31 | Skr98.69 Million ≈ $10.62 Million |
+28.53% |
| 2013-12-31 | Skr76.79 Million ≈ $8.26 Million |
+6.41% |
| 2012-12-31 | Skr72.16 Million ≈ $7.77 Million |
-2.55% |
| 2011-12-31 | Skr74.05 Million ≈ $7.97 Million |
+22.07% |
| 2010-12-31 | Skr60.66 Million ≈ $6.53 Million |
-- |
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more